This page shows the latest Questcor news and features for those working in and with pharma, biotech and healthcare.
The NDA approval was awarded to Acthar’s earlier owner Questcor, which was acquired by Mallinckrodt for $5.6bn in 2014.
Questcor allegedly increased the price to $750 immediately after buying the asset but the big jump was still to come. ... The price continued to tick up over the following years, both before and after Mallinckrodt paid $5.6bn to acquire Questcor in 2014
bought Cadence Pharma for $1.3bn, Questcor for $6.5bn, immunotherapy outfit Therakos for $1.3bn and nuclear imaging specialist IBA Molecular for £690m in the last three years.
Ikaria. In the previous year it shelled out $5.6bn for Questcor Pharma - getting hold of fast-growing autoimmune and inflammatory drug Acthar (repository corticotropin injection) - and another $1.3bn for
This includes the $5.6bn deal for Questcor Pharmaceuticals last year and its purchase of Cadence Pharmaceuticals for $1.3bn.
Under the terms of the deal, Questcor's shareholders will receive $30 in cash and 0.897 Mallinckrodt shares for each share they own. ... Trudeau will be CEO of the combined company, while three other Questcor executive, including CEO Don Bailey, will
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.
Of the remaining 18 top 21 deals this month, 12 involved wholesale takeovers with deals in Devices (Biomet/ Zimmer Holdings, AccessClosure/ Cardinal Health; New Wave Surgical/ Covidien), Generics/ Speciality Pharma (Questcor/ ... Whilst this is a 60-year
165. Novartis / Questcor. Development rights. Rights to develop Synacthen (tetracosactide, melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune &inflammatory conditions).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Michael Aldridge joins from Australian early development company Xenome. US biopharma Questcor Pharmaceuticals has named Michael Aldridge as its first senior VP, corporate strategic development. ... Development programmes that complement Acthar are also
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...